menu
    • menu
    [{"orgOrder":0,"company":"Nippon Kayaku","sponsor":"Solasia Pharma KK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Cytotoxic Drug","year":"2021","type":"Licensing Agreement","leadProduct":"Darinaparsin","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase II","graph3":"Nippon Kayaku","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nippon Kayaku \/ Solasia Pharma KK","highestDevelopmentStatusID":"8","companyTruncated":"Nippon Kayaku \/ Solasia Pharma KK"}]

    Find Clinical Drug Pipeline Developments & Deals by Nippon Kayaku

    Menu

    Nippon Kayaku

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nippon Kayaku

                            Japan arrow
                            German Wound Congress
                            Not Confirmed

                            Nippon Kayaku

                            Japan arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Darinaparsin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Solasia Pharma KK

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Solasia and Nippon Kayaku Announce License Agreement in Japan for New Drug Candidate DARINAPARSIN (SP-02)

                            Details : Under the license agreement, Solasia and Nippon Kayaku will make further efforts to provide a new treatment option to patient suffering from PTCL and for marketing rights to darinaparsin.

                            Product Name : SP-02

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            October 26, 2021

                            Lead Product(s) : Darinaparsin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Solasia Pharma KK

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth